The combination of peptide therapy and lifestyle modification leads to greater weight loss than using one intervention alone, he says
Appetite suppression through dopamine modulation Central appetite control: Tesofensine acts on hypothalamus Affects arcuate nucleus (appetite center) Different pathway from GLP-1 receptors Direct neurotransmitter modulation Rapid onset (hours not days) Dopamine's role in eating: Mediates food reward (hedonic eating) High-dopamine = reduced food seeking Decreases obsessive food thoughts Reduces binge eating tendencies Similar to ADHD medication effects Subjective appetite changes reported: Reduced hunger (moderate, not as strong as semaglutide ) Less food preoccupation Earlier satiety (smaller portions satisfying) Reduced cravings especially for high-calorie foods More mental focus on non-food activities Appetite suppression comparison: Why dopamine approach different: Addresses psychological/behavioral eating Reduces food as reward behavior Helps with emotional eating Less GI side effects than GLP-1s But creates stimulant-like dependency risk Clinical trial results and efficacy Evidence from human studies
The clearest evidence comes from SURMOUNT-4, where adults who had lost an average of 20.9% on Mounjaro over 36 weeks were then either continued on the drug or switched to placebo for another year
The drug, retatrutide, is designed to lower blood sugar, reduce appetite and increase energy expenditure
Orforglipron received FDA approval under the brand name Foundayo
Women going through hormonal transitions often need a more nuanced approach, which microdosing can provide
